• Genprex posted a net loss of USD 4.45 million for the three months ended June 30, 2026, narrowing 5% year over year.
• Research and development expense rose 7% to USD 2.68 million, driven by higher diabetes preclinical work and biomarker research.
• General and administrative costs fell 17% to USD 1.8 million on lower professional services and related expenses.
• Cash and cash equivalents totaled USD 15.15 million at June 30, 2026; net cash used in operating activities was USD 8.28 million.
• Genprex estimated cash runway into the second half of 2027 while Acclaim-1 and Acclaim-3 continue enrolling; Acclaim-3 interim enrollment targeted by end-2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genprex Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-027846), on August 14, 2026, and is solely responsible for the information contained therein.